• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Inventory of New Drug Targets in 2023 roger
    May 21, 2024
    In 2023, 49 new drugs received their first approval in the United States, the European Union, and Japan.
  • Astellas Initiates Phase 3 Clinical Trials for Fezolinetant biospectrumasia
    August 08, 2019
    Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist. The first trials of the BRIGHT SKY™ clinical development program will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing VMS frequency and severity.
  • Astellas Initiates Phase 3 Clinical Trials for Fezolinetant biospectrumasia
    August 08, 2019
    Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist. The first trials of the BRIGHT SKY™ clinical development program will evaluate the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing VMS frequency and severity.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service